Chris Toth obituary and dead, CEO of Proposed Kidney Care Spinoff

Baxter International Inc. (NYSE:BAX), a prominent global medtech leader, has announced the appointment of Chris Toth as the Chief Executive Officer (CEO) for the planned spinoff of its Renal Care and Acute Therapies businesses. Until the completion of the spinoff, contingent upon meeting customary conditions and expected to transpire by July 2024 or earlier, Mr. Toth will assume the role of Executive Vice President and Group President, Kidney Care. Effective June 1, 2023, he will report directly to Baxter’s Chairman, President, and CEO, José (Joe) E. Almeida.

Mr. Almeida expressed confidence in Mr. Toth’s suitability for leading the proposed spinoff, citing his extensive global healthcare experience, operational expertise, patient- and customer-centric approach, and commitment to healthcare access and quality of care. He emphasized Toth’s proven track record in building high-performance cultures, driving profitable growth, and fostering innovation. Almeida believes Toth’s leadership will not only build on the new company’s 70-year legacy but also propel it toward new successes.

As previously disclosed, Baxter’s plan involves spinning off its Renal Care and Acute Therapies businesses into an independent, publicly traded company named Kidney Co. The new entity will leverage its leading product portfolio, diverse geographic footprint, extensive commercial operations, and robust service capabilities supporting therapies in various settings, including home, clinic, and intensive care units (ICUs). Operating as a standalone entity, Kidney Co will have its investment priorities and enhanced management focus, positioning it to pursue growth opportunities and invest in innovation more effectively.

Mr. Toth expressed his honor and enthusiasm to lead the proposed Kidney Co, highlighting Baxter’s Kidney Care enterprise as a global industry leader, serving over one million patients annually. He emphasized his commitment to working with dedicated colleagues to create value for patients, providers, future investors, and other stakeholder communities served by Kidney Co.

Scroll to Top